Scandinavian ChemoTech and its CEO Mohan Frick participates and presents at the Emerging Medtech Summit in California, USA

Scandinavian ChemoTech and its CEO Mohan Frick has been selected to present its Tumour Specific Electroporation at the Emerging Medtech Summit in California, USA. An event bringing together the top strategists, investors, and innovators within the Medtech industry.

The summit is a 3-day event where ChemoTech and other medical device companies will present their innovations to some of the largest medical device companies and institutional investors, such as: Medtronic, Johnson & Johnson, Boston Scientific, Wells Fargo, China Bio Group and many others.

After ChemoTech’s unique platform for Tumour Specific Electroporation recently was granted two very important patents, ChemoTech actively searches for strategic alliances and collaborations for licensing its Tumour Specific Electroporation platform.

We feel honoured to have received the opportunity to present our company and our platform to an audience of this dignity. It’s going to be very interesting to see what kind of attention we can achieve during this summit”, says Mohan Frick, CEO of Scandinavian ChemoTech.

The Emerging MedTech summit will take place at the Ritz – Carlton in Laguna Niguel California 18th to 20th of February 2020.

 

To read more about this summit, please press here.

 

For further information please contact:

Mohan Frick, CEO

+46 (0)10-218 93 00

info@chemotech.se

Scandinavian ChemoTech AB (publ)

www.chemotech.se

 

ChemoTech is a life science company that possesses a great medical expertise and technical knowledge. Our latest launch of IQWave™ is an innovation within electrochemotherapy, that is adapted for the treatment of different types of tumors. ChemoTech strives to contribute to a more accessible cancer care. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Västra Hamnen Corporate Finance AB is the company's Certified Adviser. The company is headquartered at Medicon Village in Lund, in the midst of the medical technology expansionary region

About Us

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, tumor specific electroporation, available for treatment of both for humans and animals. The company is initially focused on markets in developing countries with major medical needs. There are a large number of cancer patients whose tumors for various reasons cannot be treated by conventional methods but where tumor specific electroporation can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Västra Hamnen Corporate Finance AB is the company's Certified Adviser. Read more at: www.chemotech.se.

Subscribe

Documents & Links